Literature DB >> 10716887

Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines.

P A Trimmer1, R H Swerdlow, J K Parks, P Keeney, J P Bennett, S W Miller, R E Davis, W D Parker.   

Abstract

Diseases linked to defective mitochondrial function are characterized by morphologically abnormal, swollen mitochondria with distorted cristae. Several lines of evidence now suggest that sporadic forms of Parkinson's disease (PD) and Alzheimer's disease (AD) are linked to mitochondrial dysfunction arising from defects in mitochondrial DNA (mtDNA). Human neuroblastoma (SH-SY5Y) cells that are deficient in mtDNA (Rho(0)) were repopulated with mitochondria from AD or PD patients or age-matched controls. These cytoplasmic hybrid (cybrid) cell lines differ only in the source of their mtDNA. Differences between cybrid cell lines therefore arise from differences in mtDNA and provide a model for the study of how impaired mitochondrial function alters the mitochondria themselves and how these changes adversely affect the neuronal cells they occupy. Cybrid cell mitochondria were labeled with the mitochondrial membrane potential-sensitive dye, JC-1. Analysis of these JC-1 labeled mitochondria by confocal microscopy revealed that mitochondrial membrane potential was significantly reduced in both PD and AD cybrid cells when compared with controls. Ultrastructural examination showed that control cybrid cells contained small, morphologically normal, round or oval mitochondria with a dark matrix and regular distribution of cristae. PD cybrid cells contained a significant and increased percentage of mitochondria that were enlarged or swollen and had a pale matrix with few remaining cristae (0.26-0.65 microm(2)). AD cybrid cells also contained a significantly increased percentage of enlarged or swollen mitochondria (0.25-5.0 microm(2)) that had a pale matrix and few remaining cristae. Other pathological features such as crystal-like intramitochondrial inclusions and cytoplasmic inclusion bodies were also found in PD and AD cybrids. These observations suggest that transfer of PD or AD mtDNA into Rho(0) cells was sufficient to produce pathological changes in mitochondrial ultrastructure that are similar to those seen in other mitochondrial disorders. These data were reported in abstract form (Trimmer et al., 1998, Soc. Neurosci. Abstr. 24: 476). Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716887     DOI: 10.1006/exnr.2000.7333

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  113 in total

1.  Dissipation of potassium and proton gradients inhibits mitochondrial hyperpolarization and cytochrome c release during neural apoptosis.

Authors:  M Poppe; C Reimertz; H Düssmann; A J Krohn; C M Luetjens; D Böckelmann; A L Nieminen; D Kögel; J H Prehn
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

Review 2.  Stem cell-based models and therapies for neurodegenerative diseases.

Authors:  Shilpa Iyer; Khaled Alsayegh; Sheena Abraham; Raj R Rao
Journal:  Crit Rev Biomed Eng       Date:  2009

3.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

Authors:  Shengjun Chang; Tian ran Ma; R Dennis Miranda; Maureen E Balestra; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

Review 4.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

5.  Gclc deficiency in mouse CNS causes mitochondrial damage and neurodegeneration.

Authors:  Weiyi Feng; Mariana Rosca; Yuxuan Fan; Yufen Hu; Pingfu Feng; Hyoung-Gon Lee; Vincent M Monnier; Xingjun Fan
Journal:  Hum Mol Genet       Date:  2017-04-01       Impact factor: 6.150

Review 6.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

Authors:  Ruben K Dagda; Jianhui Zhu; Charleen T Chu
Journal:  Mitochondrion       Date:  2009-06-27       Impact factor: 4.160

Review 7.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

Review 8.  Oxidative stress signaling in Alzheimer's disease.

Authors:  B Su; X Wang; A Nunomura; P I Moreira; H-gon Lee; G Perry; M A Smith; X Zhu
Journal:  Curr Alzheimer Res       Date:  2008-12       Impact factor: 3.498

9.  Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.

Authors:  Taj D King; Buffie Clodfelder-Miller; Keri A Barksdale; Gautam N Bijur
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

10.  Antioxidants Rescue Mitochondrial Transport in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.

Authors:  Qing Yu; Du Fang; Russell Howard Swerdlow; Haiyang Yu; John Xi Chen; Shirley ShiDu Yan
Journal:  J Alzheimers Dis       Date:  2016-09-06       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.